Response and Toxicity to the Second Course of 3 Cycles of (177)Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: The [(177)Lu]Lu-PSMA radioligand therapy (PSMA-RLT) has emerged as a successful treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC). Nevertheless, the therapeutic protocol of this treatment is still heterogeneous in many centers, in terms of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasul, Sazan, Wollenweber, Tim, Zisser, Lucia, Kretschmer-Chott, Elisabeth, Grubmüller, Bernhard, Kramer, Gero, Shariat, Shahrokh F., Eidherr, Harald, Mitterhauser, Markus, Vraka, Chrysoula, Langsteger, Werner, Hacker, Marcus, Haug, Alexander R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160614/
https://www.ncbi.nlm.nih.gov/pubmed/34065303
http://dx.doi.org/10.3390/cancers13102489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160614/
https://www.ncbi.nlm.nih.gov/pubmed/34065303
http://dx.doi.org/10.3390/cancers13102489

Ejemplares similares